Immatics N.V. (IMTX)
After hours:
| Previous Close | 10.81 |
| Open | 10.78 |
| Bid | 10.91 x 400 |
| Ask | 10.97 x 200 |
| Day's Range | 10.60 - 10.96 |
| 52 Week Range | 7.15 - 13.16 |
| Volume | |
| Avg. Volume | 462,690 |
| Market Cap | 1.129B |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.30 |
| Earnings Date | Aug 15, 2024 - Aug 19, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.01 |
GlobeNewswireImmatics Announces First Quarter 2024 Financial Results and Business Update
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor shrinkage achieved in 87% of patients; median duration of response of 13.5 months including 11/16 ongoing confirmed responses; IMA203 continues to maintain a favorable safety profileRegistration-enabling
- GlobeNewswire
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well toleratedRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 GEN1 in 2L+ melanoma planned to begin in 2024 Next data update on IMA203 GEN1 and IMA203CD8 GEN2 planned for 2H 2024 First clinical data updates for Immatics’ next-generation TCR Bispe
Simply Wall St.With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
Key Insights Institutions' substantial holdings in Immatics implies that they have significant influence over the...
